169 / 172
169
refractory to anti-tumor necrosis factor therapy. Arthritis
Rheum 2008;59:785-93.
187. Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin
M, et al. Sustained benefit in rheumatoid arthritis following
one course of rituximab: improvements in physical function
over 2 years. Rheumatology (Oxford) 2006; 45:1505-13.
188. Emery P, Fleischmann R, Filipowicz-Sosnowska A,
Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy
and safety of rituximab in patients with active rheumatoid
arthritis despite methotrexate treatment: results of a phase IIB
randomized, double-blind, placebo-controlled, dose-ranging
trial. Arthritis Rheum 2006;54:1390-400.
189. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-
Sosnowska A, Emery P, Close DR, et al.Efficacy of B-cell-
targeted therapy with rituximab in patients with rheumatoid
arthritis. N Engl J Med 2004; 350: 2572-81.
190.Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R,
Halland AM, Vernon E, et al. Tocilizumab inhibits structural
joint damage in rheumatoid arthritis patients with inadequate
responses to methotrexate: results from the double-blind
treatment phase of a randomized placebo-controlled trial of
tocilizumab safety and prevention of structural joint damage at
one year. Arthritis Rheum 2011; 63: 609-21.
191.Hashimoto J, Garnero P, van der Heijde D, Miyasaka N,
Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-
receptor antibody (tocilizumab) monotherapy is more effective
in slowing radiographic progression in patients with
rheumatoid arthritis at high baseline risk for structural
damage evaluated with levels of biomarkers, radiography, and
BMI: data from the SAMURAI study. Mod Rheumatol
2011;21:10-5.
192.Genovese MC, McKay JD, Nasonov EL, Mysler EF, da
Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition
with tocilizumab reduces disease activity in rheumatoid